Precision Neuroscience Corp. recently raised $102 million in a series C funding round for its AI-powered brain–computer interface (BCI) technology, the Layer 7 Cortical Interface. The funding comes as interest in the technology heats up as clinical trials show that BCI devices are capable of transforming the lives of people with disabilities.

Taipei, Taiwan- and Watertown, Mass.-based Syncell recently raised $15 million in series A financing to advance its subcellular protein purification and spatial proteomics analysis product called Microscoop Mint, based on its Microscoop platform technology.

AI-powered drug R&D platform firm Oncocross Co. Ltd. is leading the procession of year-end Korea biotech IPOs this week, pricing an offering of about 11.85 million shares on the Korea Exchange at ₩7,300 each for gross proceeds of ₩85.56 billion (US$59.5 million).

Promise Bio Ltd. emerged from stealth with $8.3 million in seed investment for its precision medicine platform, which addresses immune-mediated diseases.

Lanua Medical Ltd. raised €6 million (US$6.3 million) in seed funding for its Encore device, which is designed to enhance embolization procedures. The funds will be used to accelerate the development of the technology as well as expand operations into the U.S. The funding round was co-led by Elkstone and Atlantic Bridge, with participation from Enterprise Ireland and Furthr VC.